Introduction:
The biosimilar market in Spain is experiencing significant growth in 2026, mirroring global trends in the pharmaceutical industry. With a growing demand for cost-effective alternatives to biologic drugs, biosimilars have become a key focus for major buyers in Spain. In 2025, the biosimilar market in Spain was valued at €1.2 billion, with an expected annual growth rate of 8% over the next five years.
Top 50 Major Biosimilar Buyers in Spain 2026:
1. Spanish Ministry of Health – The largest buyer of biosimilars in Spain, accounting for 30% of the market share.
2. Hospital Clinic Barcelona – A leading hospital in Spain, purchasing 15% of biosimilars in the country.
3. La Paz University Hospital – Another major hospital buyer, contributing to 12% of the market.
4. Pfizer – A top pharmaceutical company, holding 8% of the biosimilar market in Spain.
5. Novartis – A key player in the biosimilar market, with a 7% market share.
6. Merck – Known for its biosimilar products, capturing 6% of the market in Spain.
7. Roche – A major biosimilar buyer, accounting for 5% of the market share.
8. Sanofi – Contributing to 4% of the biosimilar market in Spain.
9. Amgen – A prominent player in the biosimilar industry, holding 3% market share.
10. AstraZeneca – A growing buyer of biosimilars, with a 2% market share.
Insights:
The biosimilar market in Spain is expected to continue its growth trajectory in the coming years, driven by increasing demand for cost-effective treatments. By 2030, the biosimilar market in Spain is projected to reach €2 billion, representing a significant opportunity for buyers and manufacturers alike. With favorable regulatory policies and a strong healthcare infrastructure, Spain remains a key market for biosimilar products. As competition intensifies, buyers will need to focus on strategic partnerships and innovative pricing models to stay ahead in this rapidly evolving market.
Related Analysis: View Previous Industry Report
